We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

149 hedge funds and large institutions have $1.47B invested in Acceleron Pharma in 2017 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 55 increasing their positions, 35 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

57% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 35

41% more capital invested

Capital invested by funds: $1.05B → $1.47B (+$425M)

16% more funds holding

Funds holding: 128 → 149 (+21)

78% less call options, than puts

Call options by funds: $2.48M | Put options by funds: $11.5M

Holders
149
Holders Change
+21
Holders Change %
+16.41%
% of All Funds
3.71%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.15%
New
32
Increased
55
Reduced
35
Closed
10
Calls
$2.48M
Puts
$11.5M
Net Calls
-$9.06M
Net Calls Change
-$3.61M

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$33.4M
2
PA
Perceptive Advisors
New York
+$31.4M
3
Citigroup
Citigroup
New York
+$28.8M
4
DM
Deerfield Management
New York
+$21.3M
5
Deutsche Bank
Deutsche Bank
Germany
+$18.6M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$34.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.1M
3
GPP
Great Point Partners
Connecticut
-$11.2M
4
Millennium Management
Millennium Management
New York
-$6.39M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$4.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
51
Opaleye Management
Massachusetts
$3.79M +$52.1K +1,500 +2%
Bank of America
52
Bank of America
North Carolina
$3.64M +$665K +19,162 +24%
USAA
53
United Services Automobile Association
Texas
$3.41M +$611K +17,600 +24%
CS
54
Credit Suisse
Switzerland
$3.36M -$1.52M -43,902 -33%
JP Morgan Chase
55
JP Morgan Chase
New York
$3.29M +$3.19M +91,900 New
TCIM
56
TIAA CREF Investment Management
New York
$3.13M -$82K -2,362 -3%
Lord, Abbett & Co
57
Lord, Abbett & Co
New Jersey
$3.1M -$168K -4,839 -6%
Prudential Financial
58
Prudential Financial
New Jersey
$3.02M +$2.81M +81,010 New
Tudor Investment Corp
59
Tudor Investment Corp
Connecticut
$2.97M +$2.31M +66,662 +521%
Morgan Stanley
60
Morgan Stanley
New York
$2.92M +$439K +12,649 +19%
HLA
61
Hamilton Lane Advisors
Pennsylvania
$2.8M -$278K -8,000 -10%
CAM
62
Cormorant Asset Management
Massachusetts
$2.8M – – –
Alyeska Investment Group
63
Alyeska Investment Group
Illinois
$2.8M +$2.6M +75,000 New
Point72 Asset Management
64
Point72 Asset Management
Connecticut
$2.72M +$2.53M +72,900 New
IHM
65
Iguana Healthcare Management
New York
$2.61M +$2.43M +70,000 New
GC
66
Guggenheim Capital
Illinois
$2.43M -$49.4K -1,423 -2%
PP
67
PDT Partners
New York
$2.4M – – –
Swiss National Bank
68
Swiss National Bank
Switzerland
$2.33M +$417K +12,000 +24%
TD Asset Management
69
TD Asset Management
Ontario, Canada
$2.29M -$601K -17,300 -22%
MOACM
70
Mutual of America Capital Management
New York
$2.25M – – –
TCM
71
Tekla Capital Management
Massachusetts
$2.23M – – –
TA
72
Teachers Advisors
New York
$2.19M +$22.3K +642 +1%
PIM
73
Platinum Investment Management
Australia
$2.18M -$364K -10,500 -15%
EI
74
EAM Investors
California
$2.11M +$1.96M +56,427 New
State of New Jersey Common Pension Fund D
75
State of New Jersey Common Pension Fund D
New Jersey
$1.98M +$1.21M +35,000 +194%
1 2
3
4 5

XLRN Hedge Fund Activity: Q3 2017 in Review

149 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2017, worth a combined $1.47B — up 41% from $1.05B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new XLRN positions and 10 closed out — a net gain of 22 holders — while 55 added to existing stakes and 35 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $33.4M. The largest seller was Fidelity Investments, cutting an estimated $34.9M.

  • 149 institutional investors held Acceleron Pharma (XLRN) as of Q3 2017, up from 128 in Q2 2017.
  • Funds reported $1.47B of Acceleron Pharma stock for Q3 2017, up 41% quarter-over-quarter.
  • 32 funds opened new Acceleron Pharma positions in Q3 2017 and 10 closed out, a net change of +22 holders.
  • The largest Acceleron Pharma buyer in Q3 2017 was Farallon Capital Management, an estimated $33.4M added.
  • The largest Acceleron Pharma seller in Q3 2017 was Fidelity Investments, an estimated $34.9M sold.

Based on aggregated 13F filings for Q3 2017.